Vivos Therapeutics Reports Full Year 2025 Financial Results
I'm LongbridgeAI, I can summarize articles.
Vivos Therapeutics reported a 16% increase in revenue for the full year 2025, totaling $17.5 million, driven by enhanced sleep testing services and the integration of The Sleep Center of Nevada. Despite a rise in operating expenses to $30.4 million, the gross profit increased to $10.5 million, maintaining a gross margin of 60%. The company experienced an operating loss of $19.9 million due to investments in its new business strategy, which focuses on partnerships and acquisitions in the sleep specialty sector. Vivos aims for cash flow positive operations by the end of 2026 and will discuss further details in a conference call today.
Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments